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Abstract 
 
Diagnosing and monitoring the treatment of people with diabetes is a global issue and 
uses considerable resources in laboratories and clinics worldwide. Hemoglobin A1c 
(HbA1c) has been the mainstay of monitoring glycaemic control in people with diabetes 
for many years and more recently it has been advocated as a diagnostic tool for type 
2 diabetes (T2DM). Good analytical performance is key to the successful use of any 
laboratory test but is critical when considering using the test to diagnose disease, 
especially when the potential number of diagnoses could exceed 500 million people. 
Very small variations in bias or increased imprecision could lead to either a missed 
diagnosis or over diagnosis of the disease and given the scale of the global disease 
burden this may mean erroneous categorization of potentially millions of people. 
Fundamental to good performance of diagnostic testing is standardization, with defined 
reference material and measurement procedures. In this review we discuss the 
historical steps to first harmonize HbA1c testing, followed by the global standardization 
efforts and provide an update as to the current situation and future goals for HbA1c 
testing. 
 
Introduction 
 
The global burden of diabetes, and its complications, is increasing rapidly and it is 
estimated that by 2049, 629 million people will have the disease (1). Approximately 
one in two of those with diabetes do not know they have the disease. It is essential that 
there is a low cost, reliable and robust tool for diagnosing and monitoring disease 
progression. Haemoglobin A1c (HbA1c) has long been accepted as a monitoring tool 
for diabetes but more recently has also been advocated as a diagnostic tool for type 2 
diabetes (T2DM) (2-4).  
 
The Diabetes Control and Complications Trial (DCCT) study in people with type 1 
diabetes mellitus, which was published in 1993, clearly demonstrated that the risk of 
the development and progression of micro-vascular complications was closely related 
to the degree of glycaemic control (5). Long term follow up studies showed that macro 
vascular complications were also correlated with increasing HbA1c levels (6). At the 
same time as the DCCT study the UKPDS trial addressed improving glycaemic control 
in patients with T2DM and similarly demonstrated that improved control, evidenced by 
lower HbA1c values, resulted in improved patient outcomes (7). Since these studies 
were completed numerous large scale studies have added to our understanding of 
diabetes treatments and management but HbA1c remains at the heart of new 
treatment regimes (8-16). Treatment targets have moved away from those initially 
determined by those early studies and are now based on multiple factors such as age 
of the person, duration of disease, co-morbidities and likely compliance with therapy 
(17).  
 
In 2011 the WHO advocated the use of HbA1c for the diagnosis of diabetes at a value 
of 48mmol/mol (6.5%), in line with American Diabetes Association (ADA) 
recommendations. The WHO guidance categorically states that “provided that 
stringent quality assurance tests are in place and assays are standardised to criteria 
aligned to the international reference values” (3). It is essential therefore that 
manufacturers of HbA1c methods, used for diagnosis of diabetes, are able to 
demonstrate alignment to the IFCC reference measurement procedure and perform 
well in quality assurance schemes with accuracy based targets (18-25). In this review 
we detail the current state of the art of HbA1c measurement and standardization, and 
highlight the key roles play by different organisations and laboratory users in the 
determination of high quality and accurate HbA1c values to ensure optimal patient 
care.  
 
What is HbA1c? 
 
HbA1c is formed when glucose binds to the N-terminal valine of the beta chain of an 
haemoglobin molecule. The glycation process is non-enzymatic, therefore it is only 
dependent on time, glucose concentration and haemoglobin levels. Red blood cells 
are generally thought to circulate for around 106 days with a variation of ± 20% (26) 
and so HbA1c represents the average glucose concentration that the Hb is exposed to 
over a period of around 106 days. The distribution of red blood cells with time means 
that the HbA1c is a greater reflection of the preceding 30-60 days. This integration of 
glucose exposure over time makes HbA1c a valuable marker in assessing glycaemic 
control, over a longer period of time than can be assessed using glucose which only 
indicates glycaemia at a single time point.  
 Method principles for the measurement of HbA1c  
 
There are currently more than 100 HbA1c assays available on the market all of which 
are based on one of two principles: separation based on charge differences and 
separation based on structural differences, which occur when glucose binds to Hb. The 
former principle is used in ion-exchange chromatography and electrophoresis-based 
assays, whilst the latter principle is used in immunoassays, assays based on boronate 
affinity chromatography and enzymatic methods.  
 
Methods based on charge differences 
 
Methods based on charge differences depend on the extra negative charge that occurs 
when glucose is attached to the N-terminal valine of the HbA β-chain. Examples of 
such methods are cation-exchange chromatography and electrophoresis. Cation-
exchange chromatography is a process that allows the separation of a mixture of 
proteins based on the charge properties of the molecules in the mixture. Charged 
haemoglobins and other haemoglobin components are eluted at varying times 
depending upon the net charge of the molecule in relation to a gradient of increasing 
ionic strength buffers passed through a cation-exchange column.  
 
Capillary electrophoresis uses the principle of liquid-flow capillary electrophoresis in 
free solution. With this technique, charged molecules are separated by their 
electrophoretic mobility in an alkaline buffer at a specific pH. The separation of the 
different haemoglobin fractions takes place in silica capillary tubes and the migration 
is performed at high voltage (e.g. 9800 volts) with temperature control using a Peltier 
device. The haemoglobins are detected at an absorption wavelength of 414 nm at the 
cathodic end of the capillary using an optical detector (27). 
 
 
Methods based on structural differences  
 
Affinity separation is based on the covalent binding of cis-diols of glucose in glycated 
haemoglobin to a boronate matrixNon-glycated haemoglobin does not bind to the 
boronate matrix and is eluted directly from the column. Glycated haemoglobin initially 
binds to the column and is released when buffers with a higher affinity for the bornate 
binding sites is applied, thus displacing the bound glycated haemoglobin. The resulting 
chromatogram shows two peaks, a non-glycated peak and a glycated peak (28).  
 
Immunoassays utilise specific anti-HbA1c antibodies that recognize the first 3, 4 or 5 
amino acids and the glucose attached to the N-terminal of the β-chain of the 
haemoglobin molecule. Total haemoglobin is measured separately using a bichromatic 
assay and the ratios of the two components are calculated. Assay designs differ 
substantially from each other, ranging from immunoturbidimetry to latex agglutination 
inhibition methods (using monoclonal antibodies) (29).  
 
 
 
The enzymatic method principle consists of two separate steps: measurement of 
glycated dipeptide, obtained by enzymatic cleavage, and measurement of total 
hemoglobin (30). The glycated dipeptide is measured by adding fructosyl peptide 
oxidase to produce hydrogen peroxide, which reacts with a coloured agent in the 
presence of peroxidase. The change in absorbance is measured to calculate HbA1c 
concentration. Hemoglobin is transformed to stable met-hemoglobin and the 
concentration of hemoglobin is determined by measuring absorbance. The ratios of the 
two components are then calculated.  
 
Advantages and disadvantages of different method principles 
 
Each of the different method principles have specific advantages and disadvantages 
and method choice will depend on clinical and analytical factors. Ion exchange 
methods are associated with good performance but are often prone to interference 
from haemoglobin variants which may yield falsely lower or higher HbA1c results. To 
identify interference from haemoglobin variants, every chromatogram needs to be 
checked for abnormal peaks; either manually or through computer programming which 
requires additional training for the healthcare professional running the instrument. 
However some rare variants may show a normal chromatogram where the Hb-variant 
is hidden under the A0 peak which gives a falsely low HbA1c result. 
 
An advantage of affinity chromatography is the absence of interference by 
haemoglobin variants or derivates such as carbamylated haemoglobin, which has led 
to this method being commonly used as the method of choice for use in patients with 
haemoglobin variants (31, 32). Rolfing et al. showed, however, that there is an 
interference with HbF >20% due to the fact that HbF does not have β-chains, which 
results in a disproportionately low glycation of this haemoglobin molecule (33). 
 
An advantage of current immunoassay methods is the high throughput volumes that 
can be achieved with these fully automated systems, which can be integrated into 
laboratory track systems and sample management facilities. Another advantage is that 
the majority of the immunoassays do not suffer interference from common 
haemoglobin variants such as HbAS, HbAC, HbAD and HbAE (34). Only some rare 
haemoglobin variants (substitution of the last 3, 4 or 5 amino acids by another amino 
acid) are known to cause interference. Capillary electrophoresis is relatively new to the 
market and can measure multiple samples at once but may have limited throughput. 
Enzymatic methods currently require a large main laboratory analyser so not suitable 
for satellite laboratories or use in diabetes clinics but can facilitate high throughput.  
 
Performance of different method principles 
 
Performance of the different method principles has improved dramatically over recent 
years and the assessment of quality is aided by the international quality standards for 
HbA1c measurement (22). The global performance criteria were recently set by the 
IFCC task force for the implantation of HbA1c standardisation and based on the use of 
sigma metrics. The targets have been defined by the task force and use the concept 
of total allowable error (TAE) which combines the effects of both bias and imprecision 
into a single measure. The criteria state that a total of error of not more than 5mmol/mol 
HbA1c at a level of 50 mmol/mol is allowed. The sigma levels are applied to define 
how often the target can be expected to fall outside of the target range. For example 
at a level of 2 one in twenty of results would be expected to fall outside of the target 
range and this is deemed acceptable.  
 There are several ways that performance can be assessed, depending on need. The 
performance of individual analysers in CLSI (35-37) protocol driven laboratory 
evaluations can be used to assess the best performance of an individual instrument. 
This has a number of uses such as evaluation of new instrument in the laboratory or, 
when performed by recognised IFCC reference lab, to give an overview of the 
performance of an instrument using with IFCC targeted samples. A more robust way 
of assessing performance is through the use of data from External Quality Assessment 
(EQA) schemes, where samples within the schemes have been targeted to IFCC 
values. These schemes provide data for multiple manufacturers and instruments over 
a wider period of time using different lot numbers of reagents and calibrators and gives 
a realistic picture of performance over time in a ‘real world’ setting (38-41). In the near 
future data form a pan European study will be published showing the performance of 
HbA1c by country and by manufacturer.  
 
 
Point-of-care instruments 
 
The principles used in point-of-care (POC) instruments are predominantly affinity 
separation, immuno-assay and lately also enzymatic. Recent evaluations of the 
performance of different HbA1c POC instruments have shown that the analytical 
performance has improved considerably in recent years. However, the diagnostic 
market is flooded with new HbA1c POC instruments from a wide range of 
manufacturers and countries and the analytical performance of these instruments is 
not yet known.  
 
One key way to determine the utility of a POC device is through thorough laboratory 
evaluations however there are a limited number of robust studies where this has been 
done. Another mechanism is through performance in EQA programmes, however 
many POC devices are not entered into such programmes due to a lack of regulation 
or waiving of regulations and therefore there is limited data around the true 
performance of these instruments (20, 23, 24, 42-46). Whereas laboratory based 
methods can be adjusted by re-calibration if a drift in calibration is identified, this is not 
possible with most POC instruments as the calibration factor is predetermined by the 
manufacturer and cannot be adjusted.  
 
Aside from the inherent analytical performance issues, control of use of the devices 
outside of the laboratory setting needs to be closely monitored and as such an 
extensive and highly managed quality framework is required before these use of these 
devices is implemented (47).  
 
Standardization of HbA1c 
 
Standardization versus harmonization 
 
It is important to understand the fundamental difference between harmonization and 
standardization. With harmonization one tries to achieve comparable results among 
different measurement procedures for the same analyte (25). It usually implies there is 
no reference measurement procedure and no defined reference material or calibrator. 
This may be due to the heterogeneity of the molecules of interest or due to 
heterogeneity in measurement principles, common with hormone or antibody 
measurement. Harmonization aims to get close agreement of values within the 
constraints described above. Standardization differs in that there is always a reference 
measurement procedure and a clearly defined and characterised analyte that is 
available as reference material. In the case of HbA1c these reference materials are 
pure A1c and pure A0 both of which are registered with the Institute for Reference 
Materials and Measurements (IRMM) (48). Harmonization is commonly achieved by 
exchanging samples and aligning results. This can be done by adjusting the results 
with a factor (slope and an intercept) so that the results match between the two 
comparator methods. With standardization one tries to achieve near identical results 
by having calibration traceable to a reference measurement procedure and to a primary 
reference calibrator. 
 
The history of standardisation of HbA1c 
 
At the time of the start of DCCT and UKPDS trials no reference material was available 
and as a consequence, the inter-laboratory CV was high (>20%) (49, 50). The 
variability in results between different HbA1c methods and the multiple ways in which 
results were reported (e.g. total glycation, HbA1 and HbA1c) made it difficult for 
physicians to compare results in clinical practice or in large scale studies.  Table 1 
details the key time points in the history of HbA1c standardisation.  
 
The DCCT and UKPDS studies used the same HbA1c measurement systems and 
close monitoring of samples in the two studies provided harmonization of the results. 
The DCCT initially utilized the Bio-Rex 70 ion exchange method before switching to 
the Bio-Rad Diamat HPLC after an evaluation to harmonize results from the two 
methods, as it provided greater automation and higher throughput (51).  Although the 
study was completed using the Bio-Rad Diamat there continued to be a comparison of 
randomly blinded study samples between the two methods to verify the continuing 
relationship throughout the remainder of the study (52). 
 
In 1996, the American Association for Clinical Chemistry (AACC) initiated the National 
Glycohemoglobin Standardisation Program (NGSP), a subcommittee for the 
standardization of glycohaemoglobin that aimed to harmonize HbA1c assays 
worldwide. At that time, no definitive primary reference method or calibrator was 
available, therefore standardization was not possible however harmonization was 
achievable. The method applied in the DCCT study was chosen as the ‘reference 
method’. In addition, a network of laboratories, that would use this primary reference 
method, and of laboratories that would use secondary reference methods, was 
established to aid manufacturers of different HbA1c methods to make their methods 
traceable to the DCCT study. The NGSP consists of a steering committee and a 
network of reference laboratories including the Central Primary Reference Laboratory 
(CPRL, n=1), backup Primary Reference Laboratories (PRL, n=3 running the Bio-Rex 
70 method used in the DCCT study) and Secondary Reference Laboratories (n=6, 
running 10 Secondary Reference Measurements Procedures (SRMPs),  routine 
methods with 4 different measurement principles) (53). The SRLs work directly with 
manufacturers and laboratories to assist them in harmonizing their methods, and 
provide data for certification of traceability to the DCCT. The SRLs are also used to 
assign values to samples of the College of American Pathologists (CAP) external 
quality survey. The SRLs are monitored monthly against the CPRL and among the 
SRMPs with 10 frozen samples. However, in this system there is no primary calibrator 
and the ‘reference method’ was subject to interference (54).  
 
Harmonization systems in Japan and Sweden 
 
In addition to the NGSP system Japan and Sweden independently developed 
harmonization schemes based on cation exchange HPLC methods. In Japan the 
KO500 method is used as a PRM and in Sweden a Mono-S cation exchange system 
is used (55, 56). Both columns are more specific than the Bio-Rex70 method which 
was used in the NGSP harmonization model but still do not give the “true” HbA1c result 
due to some degree of interference in the method. The Mono-S HPLC does not have 
defined calibrators, instead the area under the HbA1c peak in relation to the area under 
all peaks in the elution profile, is used to calculate the percentage HbA1c.   
 
The HbA1c methods in Japan are calibrated using material from the Japanese-Clinical-
Chemistry-Use Certified Reference Material (JCCRM). The standardization of HbA1c 
in Japan was initiated in 1993, and the serial reference materials from JDS Lot 1 to 
JDS Lot 5 are well certified (57). Since 2013, in Japan and abroad JDS Lot 5 is used. 
This reference material has assigned certified IFCC (mmol/mol), NGSP (%) and JDS 
(%) values measured by JDS-JSCC Network Laboratories using the KO500 Method. 
The IFCC values were assigned by PRMs in the IFCC HbA1c Laboratory Network and 
the NGSP values were assigned by the Japanese NGSP SRMP (=ASRL#1) using the 
NGSP CPRL reference panel (100 specimens) as a calibrator. The Japanese NGSP 
SRMP is monitored monthly against the CPRL and among the 10 SRMPs in the NGSP 
network with 10 frozen samples. 
 
In 2010 the JDS decided to report NGSP values as well JDS values with the purpose 
of international clinical harmonization. The NGSP values were expressed simply by 
adding 0.4% to the JDS values (58). The 0.4% is the unspecificity of the NGSP PRM 
compared to the KO500 method. Which serves to highlight the significant level of 
interference in the harmonization methods. 
 
Since April 2014 only NGSP values have been used in the clinical practice of Japan, 
which offers some form of harmonization but it is unclear why SI units and indeed IFCC 
values were not adopted. 
 
 
The need for standardization 
 
With the progress of technology and identification of interference in the Bio-Rex 
method, it was no longer scientifically acceptable to continue without a robust 
standardization process, constituting a true primary reference measurement procedure 
and defined primary reference materials. In addition legislation for in vitro diagnostic 
medical devices for manufacturers who sell instruments in European Community 
demands that manufacturers must guarantee the traceability of their routine tests to 
reference methods and materials of higher metrological order. This is further required 
by ISO/TC212 standards which dictate that manufacturers have documented 
traceability to assigned values and to a reference method (59). This is not possible with 
the NGSP harmonization model and thus there was a requirement for a true 
standardization process and the development of a PRM and pure calibrators.  
 
IFCC standardization 
 
An IFCC Working Group for the standardisation of HbA1c was established in 1994 to 
develop a standard for HbA1c, consisting of almost pure HbA1c and HbA0, and a 
primary reference method for HbA1c. Whilst this was ongoing, the AACC and the ADA 
accepted harmonization via NGSP as an interim solution until true standardisation was 
achieved. The IFCC Working Group on HbA1c Standardisation succeeded in 
producing reference material and defining a reference measurement procedure, which 
was published in 2002 (60) (Figures 1 and 2). In addition, a laboratory network was 
established, which included the two reference methods, i.e. mass spectroscopy and 
capillary electrophoresis (61). Currently there are 21 laboratories worldwide running 
the IFCC PRM either using the HPLC-CE method or HPLC-MS. Each network 
laboratory used prepared mixtures of purified HbA1c and HbA0 as calibrators (62). The 
main task of the IFCC Network of Reference Laboratories for HbA1c is to assign values 
to secondary reference material and to collaborate with manufacturers of diagnostic 
devices and External Quality Assessment Schemes (EQAS) organisers to ensure 
methods are traceable to the RMP. Figure 3 shows the traceability chain of the IFCC 
standardization of HbA1c. This process provides an unbroken chain between the 
patient results and the primary reference material, thus ensuring that patients get the 
right results, which can be universally compared against clinical targets and large scale 
study data. 
 
Why does the IFCC RMP report values in mmol/mol and not %? 
 
The international consensus statement on the measurement and reporting of HbA1c 
values states that “HbA1c results are to be reported by clinical laboratories worldwide 
in SI (Sistème Internationale) units (mmol/mol – no decimals) and derived NGSP units 
(% – one decimal), using the IFCC-NGSP master equation (DCCT units).” 
 
There are two factors that influenced the decision to change the reporting units to 
mmol/mol. Firstly, the difference between the Bio-Rex values and the true values 
determined by the IFCC RMP is approximately 2%, which represents the interference 
seen in the Bio-Rex method. For examples to change HbA1c values would be reduced 
by approximately 2% (i.e 6% would become 4%) although the relationship is not 
completely linear. This substantial change would cause considerable disruption and 
global confusion, however it would not be scientifically sound to adjust the true values 
either. As a change was needed, the change to completely different numbers and units 
was seen as less likely to be detrimental to patient and clinical understanding and care 
than a small reduction in numbers. This was proven to be the case in a study that 
showed that there was no change in glycaemic control as a result of the shift in reported 
units (63). Secondly, by law in Europe all test values must be reported in SI units where 
possible and % is not classed as an SI unit. 
 
Can I relate IFCC standardized values to NGSP/DCCT harmonized values? 
 
The simple answer is yes. The interference seen in the Bio-Rex system is constant 
meaning that inter-comparison studies between the two networks allows for a master 
equation to be applied to convert values between the two systems. In addition there 
are master equations that link the JDS and IFCC systems (64, 65). This allows 
clinicians and patients to convert between NGSP harmonized % values and the IFCC 
SI values with no loss of traceability to the DCCT trial results. Whilst more recent 
studies now inform clinical guidance many still wish to convert back to more familiar % 
values and this is achieved using the master equation. To facilitate this a number of 
clinical organizations have online conversion calculators (66).  
 
Standardization versus calibration 
 
One source of confusion is the difference between standardization and calibration of 
instruments, with the terms often being used interchangeably. Standardization is the 
global process, led by the IFCC reference network and supporting committees that 
produces primary and secondary calibrators directly traceable to a defined measurand, 
in the case of HbA1c the defined measurand is Beta N-(1-deoxyfructos-1-yl) haemoglobin 
(67). These calibrators are provided to manufacturers who use them to assign values 
to their own calibrators that are provided to the end user to calibrate their instrument. 
Calibration is the process by which the values generated by the instrument when 
measuring calibration material are compared with the expected values of the 
calibration material and used to adjust the set point for future measurements.  
 
 
How to I standardize HbA1c in my laboratory or my country?  
 
Again there is a simple answer to this, for the laboratory you don’t need to implement 
your own standardization. Standardization is not done at a laboratory level, instead, in 
order to produce IFCC standardized HbA1c values it is important to use instruments 
where the manufacturer can demonstrate are traceable to the IFCC RMP. 
Manufacturers are responsible for demonstrating that they are working with the IFCC 
HbA1c network to be traceable to the IFCC PRMP. However, it is the responsibility of 
an individual laboratory is to choose an HbA1c method which is performing well in 
accuracy based external quality schemes. An IFCC or an NGSP certification does not 
always reflect the analytical performance of a method in the field because certification 
is done under ideal circumstances at the manufacturer’s site often using a single lot of 
reagent and calibrators, one instrument and one application. Results in external quality 
schemes reveal the real analytical performance in the field with different reagent lot 
numbers, different instruments, different applications (whole blood or hemolysate 
mode) and different users.   
 
Individual laboratories should never use the results of an external quality scheme to 
calculate a factor to adjust laboratory values to ‘bring them in line’ with EQA data as 
this disrupts the traceability chain. If poor performance is identified in an EQA schemes 
laboratories should liaise with the manufacturer to elucidate the cause of the poor 
performance and work together to find a solution.   
 
Standardization at a country level is a more complex consideration. Healthcare 
organizations should work closely with the IFCC and manufacturers to devise an 
implementation approach that best fits the needs of that country. 
 
 
The heart of the standardization: IFCC secondary reference material 
 
At the heart of the global standardization of HbA1c methods is the scientific 
collaboration between the manufacturers and the IFCC, through the production and 
utilization of secondary reference material. The European Reference Laboratory for 
Glycohemoglobin (ERL) plays a key role in the standardization of HbA1c worldwide by 
producing the IFCC secondary calibrators (Figure 3). This secondary reference 
material, made from patient whole blood, is used by manufacturers of HbA1c methods 
to assign values to their own method-dependent calibrators. The primary reference 
calibrator can’t be used in routine HbA1c methods as it is not commutable with these 
routine methods and therefore secondary reference calibrators made from patient 
blood are needed. Commutability of reference material is of utmost importance and is 
the responsibility of the manufacturer to verify. Each year 8 calibrator pools are 
produced from at least 10 donors. The values of these calibrators are assigned by all 
of the laboratories in the IFCC network running the IFCC PRMP (HPLC-CE or HPLC-
MS, n=21) (Figure 1). Once values are assigned the calibrators are provided to 
manufacturers to enable them to produce their own calibrators and ensure traceability 
to the RMP. These calibrators are generally commutable to most methods, except 
some POC devices where fresh, not frozen whole blood is required. The ERL provides 
fresh patient samples with values assigned with at least 3 SRMP in duplicate to 
manufacturers who can’t work with frozen IFCC secondary reference material. Some 
manufacturers need fresh patient samples with assigned values every week due to the 
production of new lot numbers every week. A study in 2014, where 7 HbA1c point-of-
care instruments were evaluated, showed that 3 of the evaluated instruments had a 
commutability problem with the IFCC secondary calibrator which was frozen. The 
instruments were calibrated with frozen material while it showed a negative bias with 
fresh patient samples (43, 44). 
 
These pools are also used to check the stability of the published master equations 
between the different harmonization/standardization models (65). This equation is 
continuously monitored to insure that the relationship between the “true values” (IFCC) 
and other harmonization systems remains stable. Interestingly the ERL also plays a 
key role in value assignment for NGSP and IFCC certification samples and for external 
quality assessment sample. In total the ERL has 2 IFCC PRMS, 1 NGSP PRM and 7 
IFCC SRMPs of which 5 are also NGSP SRMPs. 
 
Is there a blind spot in the standardization process? What do manufacturers do 
to ensure traceability? 
 
According to the IFCC traceability chain, manufacturers should use the IFCC 
secondary reference material to standardize their own method and generate their own 
calibration material for supply to laboratory users. Each of the major manufacturers, 
who collaborate with the IFCC network, receive 8 frozen pools once a year with values 
assigned by the whole IFCC network (n=21). Manufacturers who can’t work with frozen 
material, for examples some manufacturers of POC devices, receive the pools as fresh 
material. Every manufacturer has their own procedure to use this material to assign 
values to their own method. Some manufacturers have a master lot and they 
harmonize the new lot with this master lot using it to check if they still produce the 
correct values rather than using the secondary calibrators to assign values to their own 
calibrators. A significant issue for some manufacturers is the high frequency with which 
they generate new lot numbers making it impossible to repeatedly use the secondary 
calibrators each time. This is particular the problem for some manufacturers of POC 
instruments.  
 
Whilst a list of manufacturers who work with the IFCC is maintained it is known that 
there are a significant number of national companies around the world, who do not 
interact directly with the IFCC network but may collaborate with individual local IFCC 
Network laboratories. Despite several IFCC SRM also being NGSP SRMPs, an NGSP 
certificate does not confer direct traceability to the IFCC RMP. 
 
 
Has the standardization of HbA1c been a great success story? 
 
Prior to 1993, there was no standardization which resulted in inter-laboratory CVs 
>20% and values were not linked to clinical outcome data and were therefore difficult 
to interpret for health care providers. The aim of standardization was to reduce the 
imprecision of methods and to ensure the minimum bias from the true HbA1c values. 
The latest results of the College of American Pathology (CAP) survey showed that the 
inter-laboratory CV is now around 3.5% and only 2 of the 26 methods surveyed had a 
method specific bias >0.3% (NGSP units) (38, 39, 41, 54). Seen from this perspective 
the standardization of HbA1c has been a great success story as there has been a 
considerable improvement in analytical performance.  
 
However, there is still a considerable level of misunderstanding and confusion around 
the process of standardization and the roles of different organizations. The NGSP and 
IFCC Reference Systems serve different but complementary purposes, with the former 
being a harmonization process that applies defined acceptable limits for method 
performance that are based on historical clinical requirements and the latter being a 
standardization process that provides traceability to an accuracy base and allows for 
the application of scientifically based quality standards (22, 68). Certification of 
methods at a laboratory level is important in demonstrating good performance at that 
point in time and with the imminent introduction of IFCC laboratory certification, 
laboratories will be able to directly demonstrate that their instruments perform well in 
their own clinical or laboratory settings. To achieve this the laboratory will likely have 
to use an instrument where the manufacturer can clearly demonstrate traceability to 
the IFCC reference measurement procedure. However, this is still a snapshot of 
performance and engagement with an EQA scheme that uses samples with values 
targeted to the IFCC RMP provides a more thorough demonstration of ongoing good 
performance.  
 
 
A further issue that adds to the confusion is the use of 2 reporting units: NGSP in 
percentage units and IFCC (SI) in mmol/mol units. Whilst it is understandable that there 
may be reluctance to change, it is important to understand that the instruments are 
calibrated to the IFCC RMP and the values are then mathematically converted to the 
% values. The instruments of all the major manufacturers no longer ‘measure’ in DCCT 
units but instead apply the master equation to convert the values. For scientists and 
manufacturers it is still a complicated issue as both values need to reported in articles 
and in package inserts of the manufacturer (69). Besides that, the scale of the 
difference between the numbers means that calculations of CV’s, give different values 
using different units, CV’s calculated in SI units can’t be compared with CV’s in NGSP 
units (18). Despite a global consensus statement, written by the major organizations 
involved in diabetes care worldwide (The American Diabetes Association (ADA), the 
European Association for the Study of Diabetes (EASD), the International Diabetes 
Federation (IDF), the IFCC, the International Society for Pediatric and Adolescent 
Diabetes (ISPAD), the JDS, and the NGSP) stating that HbA1c should be reported in 
SI units and derived (=calculated with published master equation) NGSP units (69), 
this is not universally applied. In addition Japan chose to follow the NGSP and report 
HbA1c only in NGSP units with the purpose of international harmonization of HbA1c 
values which is, seen from a scientific point of view, a step back in the standardization 
of HbA1c. So, although considerable progress has been made in the standardization 
of HbA1c acceptance and understanding of the process is still lagging and there is 
need for ongoing education around this important issue. Reporting values in SI units 
(mmol/mol) does not mean that the link to the DCCT and UKPDS studies is lost as that 
link is maintained through the master equation linking the NGSP and IFCC. With the 
use of HbA1c for the diagnosis of type 2 diabetes it is critical that the correct HbA1c 
values are provided as even a small positive or negative bias in HbA1c values can lead 
to the re-categorization of disease state for potentially millions of people. 
 
Future of HbA1c. Will we still analyze HbA1c in 2030? 
 
HbA1c has been widely accepted in clinical practice for over 25 years but there are a 
number of potential new markers available that may complement or eventually 
supersede its use.  Continuous glucose monitoring (CGM) is one such development. 
Currently the CGMs are still relatively cumbersome, expensive, technically demanding 
and patients require extensive training to enable them to use the device which is 
commonly not reimbursed by many insurance companies. However, recent 
developments to miniaturize the device (as small as a rice grain) with a longer 
functional time (currently it is maximum of 14 days) have the potential to change this. 
In some diabetic centers where CGM is used a large database has been developed to 
explore the links between average mean glucose, HbA1c and clinical outcomes. 
Current evidence from the A1c-Derived Average Glucose study showed that, although 
the relationship between HbA1c and average glucose was linear, a wide variation was 
observed between individuals, meaning it is currently not considered robust enough 
for use in routine clinical practice (69, 70). However this may change with further long 
term data collection. 
 
In future clinical practice will continue to move forward as new understanding diabetes 
is gained and targets for treatment will be patient centered and individualized to that 
patient. Malka et al designed an elegant model for a personalized approach using 
existing clinical measurements to personalize prospective estimates of average 
glucose (71)anaem. They combined a mechanistic mathematical model of hemoglobin 
glycation and red blood cell kinetics with large sets of within-patient glucose 
measurements (CGM) to derive patient-specific estimates of nonglycemic 
determinants of HbA1c, including mean red blood cell age.  
 
Conclusion 
 
Whilst great advances have been made in the field of diabetes care, and HbA1c is 
rapidly becoming one of the best characterised biomarkers in laboratory science, it is 
likely that HbA1c will be the mainstay of disease diagnosis and monitoring for some 
time to come. It is essential, therefore, that the test is used correctly and more fully 
understood, with questions such as the influence of ethnicity, anaemia, 
haemoglobinopathies etc still to be fully addressed (72). In addition to this the scientific 
and clinical community still have a way to go to fully embrace the standardisation 
process and move away from historical harmonization schemes to full global 
acceptance of standardisation.  
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